# Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection

> **NCT04377659** · PHASE2 · TERMINATED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 9 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT04377659
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-05-01
- **Primary completion:** 2022-10-28
- **Final completion:** 2022-10-28
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Based on two large, multicenter, randomized trials showed no benefit to tocilizumab in this setting and study has been closed.
- **Last updated:** 2025-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04377659

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04377659, "Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04377659. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*